IL149251A0 - Diagnosis and treatment of cardiovascular conditions - Google Patents

Diagnosis and treatment of cardiovascular conditions

Info

Publication number
IL149251A0
IL149251A0 IL14925101A IL14925101A IL149251A0 IL 149251 A0 IL149251 A0 IL 149251A0 IL 14925101 A IL14925101 A IL 14925101A IL 14925101 A IL14925101 A IL 14925101A IL 149251 A0 IL149251 A0 IL 149251A0
Authority
IL
Israel
Prior art keywords
diagnosis
treatment
cardiovascular conditions
cardiovascular
conditions
Prior art date
Application number
IL14925101A
Other languages
English (en)
Original Assignee
Brigham & Womens Hospital
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital, Pfizer filed Critical Brigham & Womens Hospital
Publication of IL149251A0 publication Critical patent/IL149251A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL14925101A 2000-08-22 2001-08-21 Diagnosis and treatment of cardiovascular conditions IL149251A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22715900P 2000-08-22 2000-08-22
PCT/US2001/026089 WO2002016416A2 (fr) 2000-08-22 2001-08-21 Diagnostic et traitement d'etats cardiovasculaires

Publications (1)

Publication Number Publication Date
IL149251A0 true IL149251A0 (en) 2002-11-10

Family

ID=22852000

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14925101A IL149251A0 (en) 2000-08-22 2001-08-21 Diagnosis and treatment of cardiovascular conditions

Country Status (9)

Country Link
US (1) US20020115081A1 (fr)
EP (1) EP1311547A2 (fr)
JP (1) JP2004506443A (fr)
AU (1) AU8513901A (fr)
BR (1) BR0107157A (fr)
CA (1) CA2388061A1 (fr)
IL (1) IL149251A0 (fr)
RU (1) RU2002110275A (fr)
WO (1) WO2002016416A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090176722A9 (en) 2000-01-28 2009-07-09 Shiv Srivastava Androgen-regulated PMEPA1 gene and polypeptides
US6640135B1 (en) * 2000-04-06 2003-10-28 Cardiac Pacemakers, Inc. Apparatus and method for spatially and temporally distributing cardiac electrical stimulation
WO2001094420A1 (fr) 2000-06-05 2001-12-13 The Trustees Of Columbia University In The City Of New York Identification et utilisation des cellules progenitrices endotheliales derivees de la moelle osseuse, destinees a ameliorer la fonction du myocarde apres un accident ischemique
AU2002218026A1 (en) 2000-11-09 2002-05-21 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US6628988B2 (en) 2001-04-27 2003-09-30 Cardiac Pacemakers, Inc. Apparatus and method for reversal of myocardial remodeling with electrical stimulation
US6973349B2 (en) * 2001-12-05 2005-12-06 Cardiac Pacemakers, Inc. Method and apparatus for minimizing post-infarct ventricular remodeling
US6915160B2 (en) * 2002-02-08 2005-07-05 Cardiac Pacemakers, Inc. Dynamically optimized multisite cardiac resynchronization device
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
JP4514606B2 (ja) 2002-05-09 2010-07-28 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド 心血管疾患マーカーおよび治療標的としてのｉｌ１ｒｌ−１
US6965797B2 (en) * 2002-09-13 2005-11-15 Cardiac Pacemakers, Inc. Method and apparatus for assessing and treating myocardial wall stress
US20040186155A1 (en) * 2003-01-30 2004-09-23 Dayno Jeffrey Marc Combination therapy for the treatment or prevention of migraine
WO2005075646A1 (fr) * 2004-02-03 2005-08-18 Kurume University Peptide provenant d'une molecule d'antiapoptose induite par un stress (iex-1)
AU2006206376B2 (en) 2005-01-20 2012-03-08 University Of Rochester Thioredoxin interacting protein (TXNIP) as regulator of vascular function
US9050393B2 (en) * 2005-02-08 2015-06-09 Bruce N. Saffran Medical devices and methods for modulation of physiology using device-based surface chemistry
US7366567B2 (en) * 2005-03-23 2008-04-29 Cardiac Pacemakers, Inc. Method for treating myocardial infarction
ES2351623T3 (es) 2006-04-24 2011-02-08 Critical Care Diagnostics, Inc. Predicción de la mortalidad y detección de una enfermedad grave.
ES2380711T3 (es) 2006-05-01 2012-05-17 Critical Care Diagnostics, Inc. Diagnóstico de enfermedades cardiovasculares
US8147817B2 (en) * 2006-05-04 2012-04-03 The Brigham And Women's Hospital, Inc. IL-33 in the treatment and diagnosis of diseases and disorders
SI3093663T1 (sl) 2008-04-18 2018-10-30 Critical Care Diagnostics, Inc. Napovedovanje tveganja večjih neželenih srčno-žilnih dogodkov
WO2012141844A2 (fr) 2011-03-17 2012-10-18 Critical Care Diagnostics, Inc. Procédés de prédiction de risque d'un résultat clinique indésirable
WO2013134632A2 (fr) * 2012-03-09 2013-09-12 Fibrogen, Inc. Traitement de taux élevé de cholestérol
MX2015002254A (es) 2012-08-21 2015-05-08 Critical Care Diagnostics Inc Estratificacion de riesgo para marcador multiple.
RS60421B1 (sr) * 2012-09-07 2020-07-31 Inserm (Institut National De La Santé Et De La Rech Médicale) Inhibitorni peptidi poreklom od aktivirajućeg receptora eksprimiranog na mijeloidnim ćelijama-1 (trem-1) i trem-sličnog transkripta 1 (tlt-1) i njihove upotrebe
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
MD707Z (ro) * 2013-01-18 2014-07-31 Институт Зоологии Академии Наук Молдовы Metodă de identificare a secvenţelor polimorfe 4a/4b ale genei sintetazei endoteliale a oxidului nitric
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
FR3100714A1 (fr) * 2019-09-12 2021-03-19 L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude Argon associé à une thrombectomie en cas d’accident vasculaire cérébral ischémique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217899A (en) * 1990-08-24 1993-06-08 The General Hospital Corporation Cell stretching apparatus
EP1115872A2 (fr) * 1998-08-07 2001-07-18 Onyx Pharmaceuticals, Inc. Polypeptide chp, un ligand du pak65
EP1135494A2 (fr) * 1998-12-11 2001-09-26 Incyte Pharmaceuticals, Inc. Proteines associees a des neurones
CA2362924A1 (fr) * 1999-03-01 2000-09-08 Millennium Pharmaceuticals, Inc. Proteines secretees et acides nucleiques codant pour elles
US20030180728A1 (en) * 2002-03-22 2003-09-25 Kovacs Karl F. Human BCU399 gene, polypeptide, and uses

Also Published As

Publication number Publication date
AU8513901A (en) 2002-03-04
BR0107157A (pt) 2002-07-16
WO2002016416A2 (fr) 2002-02-28
JP2004506443A (ja) 2004-03-04
US20020115081A1 (en) 2002-08-22
RU2002110275A (ru) 2004-03-27
CA2388061A1 (fr) 2002-02-28
WO2002016416A3 (fr) 2003-03-13
EP1311547A2 (fr) 2003-05-21

Similar Documents

Publication Publication Date Title
IL149251A0 (en) Diagnosis and treatment of cardiovascular conditions
GB2368794B (en) Prevention and treatment of amyloidogenic disease
AU1166502A (en) Human ect2 and methods of use
GB9903841D0 (en) Diagnosis and treatment of cancer
IL159816A0 (en) In-vivo method and device for improving diastolic function of the left ventricle
IL158532A0 (en) Treatment and diagnosis of macrophage mediated disease
AU2002367535A8 (en) Diagnosis and treatment of vascular disease
EP1648422A4 (fr) Traitement et prevention d'accidents cardiovasculaires
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
HK1043546A1 (zh) 採用異黃酮類化合物治療心血管疾病和骨疾病
EP1335736A4 (fr) Compositions et methodes de diagnostic et de traitement de troubles cardio-vasculaires
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
GB9911772D0 (en) Diagnosis and treatment of atherosclerosis
EP1451138A4 (fr) Methode permettant d'inverser le processus de maladies cardio-vasculaires et de prevenir ces dernieres
GB2360453B (en) Treatment of skin conditions
GB2381272B (en) Diagnosis and treatment of atherosclerosis
EP1409734A4 (fr) Diagnostic et traitement du cancer
GB0008326D0 (en) Diagnosis and treatment of autism and related disorders
GB9908059D0 (en) Diagnosis and treatment of diseases
GB0120009D0 (en) Cause and effect diagnosis
EP1443953A4 (fr) Detection et traitement de lesions intravasculaires
EP1303281A4 (fr) Methodes de traitement
EP1392460A4 (fr) Hydrofluorures d'aminosilanols et leur utilisation
ZA200103250B (en) The treatment of immunomodulatory related and other diseases or conditions.
GB0024728D0 (en) Hypertension diagnosis and treatment